Related Experiment Video
Updated: Jul 6, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
[Genetic causes of the thyroid carcinomas]
S Jindrichová1, P Vlcek, B Bendlová
1Endokrinologický ustav-oddĕlení molekulární endokrinologie, Praha. sarka@obloha.cz
Casopis Lekaru Ceskych
|December 9, 2004
Summary
Genetic alterations drive thyroid cancer development. Specific mutations in genes like RET, BRAF, and p53 are linked to papillary, follicular, anaplastic, and medullary thyroid carcinomas, aiding diagnosis and potential targeted therapies.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Thyroid carcinomas are rare malignancies but comprise most endocrine tumors.
- Understanding the genetic basis of different thyroid cancer subtypes is crucial for diagnosis and treatment.
Purpose of the Study:
- To elucidate the specific genetic alterations responsible for the development of various thyroid carcinoma types.
- To highlight the potential of genetic findings for diagnostic precision, prognosis, and targeted gene therapy.
Main Methods:
- Review of genetic alterations associated with papillary, follicular, anaplastic, and medullary thyroid carcinomas.
- Identification of key gene fusions, mutations, and loss of heterozygosity events.
Main Results:
- Papillary thyroid carcinoma: Fused tyrosine kinase genes (RET, NTRK1, met) and BRAF mutations.
- Follicular thyroid carcinoma: PAX8/PPARgamma fusion and ras mutations.
- Anaplastic thyroid carcinoma: p53 gene mutations/loss of heterozygosity, often from dedifferentiation.
- Medullary thyroid carcinoma: RET proto-oncogene mutations (somatic/germline).
Conclusions:
- Specific genetic profiles characterize each thyroid carcinoma subtype.
- Identifying these genetic alternations can improve diagnostic accuracy and disease prognosis.
- These genetic insights may pave the way for future targeted gene therapies for thyroid cancer.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...